Transient ischaemic attack after spacing the dose of alirocumab: Is it advisable to reduce the doses of PCSK9 inhibitors with very low LDL-cholesterols?

  1. Piqueras Ruiz, S.
  2. Parra Virto, A.
  3. Torres do Rego, A.
  4. Demelo Rodríguez, P.
  5. Álvarez-Sala Walther, L.
Aldizkaria:
Clinica e Investigacion en Arteriosclerosis

ISSN: 1578-1879,  0214-9168

Argitalpen urtea: 2020

Alea: 32

Zenbakia: 1

Orrialdeak: 30-32

Mota: Artikulua

DOI: 10.1016/J.ARTERI.2019.04.003 GOOGLE SCHOLAR
Datuen iturria: Scopus